Institut Curie at the 2022 ASCO Annual Meeting
From June 3 to 7 in Chicago (United States), after two years of virtual meetings due to the pandemic, the world’s oncology community will reunite for the essential meeting of the American Society of Clinical Oncology (ASCO). For five days, physicians from Institut Curie across all areas of oncology will be there in full force to share their very promising results to speed up the fight against cancer.
The annual meeting of the American Society of Clinical Oncology (ASCO) will bring together the world's cancer community from June 3 to 7 in Chicago, USA. For this edition, physicians from the Institut Curie, a leading player in cancer research and treatment, will present the results of their very promising work, particularly in the fields of female cancers, digestive cancers and hematology.
Following two very unusual years in many respects, I am delighted that this year’s ASCO meeting, with its highly promising results, can be held in Chicago. Physicians from Institut Curie will present unique and original research encompassing targeted therapies, treatment combinations and supportive care, geared towards developing new therapeutic strategies. This year again we have a great many papers accepted at ASCO, a testimony to the excellence of our teams, our international reputation and the importance of the productive collaborations that bring us further in the fight against cancer, for the benefit of patients.
says Prof. Steven Le Gouill, director of the Hospital Group at Institut Curie.
Institut Curie highlights at ASCO 2022
BREAST AND GYNECOLOGICAL CANCERS
► Elderly women: highly anticipated results from a major breast cancer study
Almost half of all cancers occur in patients aged 70 and over; and the occurrence in this population will continue to rise in the coming years, bringing with it major public health challenges. This elderly portion of the population is too often excluded from therapeutic trials, which are necessary for developing appropriate treatments. The unique ASTER 70s trial, conducted on 2,000 women patients, is the first multi-center therapeutic trial based on the analysis of a prognostic biomarker for choosing to perform adjuvant chemotherapy in patients over the age of 70 after breast cancer surgery. The aim of the trial is to assess the effectiveness of post-surgical chemotherapy treatment when the tumor is aggressive (chemotherapy and hormone therapy versus hormone therapy alone). The results give information on therapeutic de-escalation and will provide valuable information in terms of quality of life, autonomy and acceptability of care. Dr. Etienne Brain, medical oncologist at Institut Curie, coordinated this ASTER 70s study sponsored by Unicancer, and will present its results orally on June 7 at the ASCO meeting.
| Final results from a phase III randomized clinical trial of adjuvant endocrine therapy ± chemotherapy in women ≥ 70 years old with ER+ HER2- breast cancer and a high genomic grade index: The Unicancer ASTER 70s trial. Session « Breast Cancer — Local / Regional / Adjuvant ». Oral presentation by Dr Etienne Brain, medical oncologist at Institut Curie, on June 7 at 6:33pm (French time) |
And also:
► Combining radiotherapy and targeted therapy to treat triple-negative breast cancer
A study coordinated by Dr. Youlia Kirova, radiotherapist oncologist at Institut Curie.
Safety and tolerability of Olaparib combined with breast radiotherapy in patients with triple negative breast cancer: final results of the RADIOPARP phase 1 trial. – Session « Breast Cancer. Local/Regional/Adjuvant ».
Poster available on June 6 at 2:00pm (French time)
► Real-life analysis of hormone therapy data in breast cancer
A study coordinated by Drs. Luc Cabel and Marcela Carausu, medical oncologists at Institut Curie.
Treatment patterns and their impact on the outcome of patients with HR+/HER2+ metastatic breast cancer in a large real-world cohort. Session « Breast Cancer—Metastatic ».
Poster available on June 6 at 2:00pm (French time)
► Advanced cervical cancer: what is the role of immunotherapy?
A study coordinated by Dr. Manuel Rodrigues and Dr. Emmanuela Romano, medical oncologists at Institut Curie.
Combination of nivolumab with chemoradiotherapy for locally advanced cervical cancer: NiCOL phase I trial. Session « Gynecologic cancer ».
Poster available on June 4 at 2:00pm (French time)
► Screening for BRCA1 and BRCA2 mutations in ovarian cancer
A study coordinated by Dr. Manuel Rodrigues, medical oncologist at Institut Curie.
Efficacy of maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer according to BRCA mutation genotype in the phase III PAOLA-1/ENGOT-ov25 trial. Session « Gynecologic cancer ».
Poster available on June 4 at 2:00pm (French time)
DIGESTIVE CANCERS
► Pancreatic cancer: an original study to assess the effectiveness of adapted physical activity
Among the different types of supportive care, adapted physical activity (APA) in patients receiving chemotherapy is a truly innovative treatment that combats fatigue and sarcopenia (cancer-related muscle loss) and improves quality of life. Its beneficial effects have already been demonstrated in patients treated for breast cancer with an adjuvant treatment. The data for digestive cancers, in particular advanced ones (inoperable), are more limited. Dr. Cindy Neuzillet, a gastroenterologist and specialist in digestive cancers at Institut Curie, is getting ready to resent the final results of a unique study that she coordinated with Prof. Pascal Hammel (AP-HP) for 8 years. Sponsored by GERCOR, this phase-3 trial, APACaP, evaluated the role of adapted physical activity among over 300 patients with advanced pancreatic cancer.
| Adapted physical activity in patients (Pts) with advanced pancreatic cancer (APACaP): Results from a prospective national randomized GERCOR trial. Session « Gastrointestinal Cancer — Gastroesophageal, Pancreatic, and Hepatobiliary ». Oral presentaton by Dr Cindy Neuzillet on June 5 at 4:48pm (French time). |
And also:
► Vaccine therapy in metastatic pancreatic cancer
A study coordinated by Dr Cindy Neuzillet, gastroenterologist at Institut Curie.
A randomized, non-comparative, phase II study of maintenance OSE2101 vaccine alone or in combination with nivolumab (nivo) or FOLFIRI after induction with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): First interim results of the TEDOPAM GERCOR D17-01 PRODIGE 63 STUDY. Session « Gastrointestinal Cancer-Gastroesophageal, Pancreatic, & Hepatobiliary ».
Poster available on June 4 at 2:00pm (French time).
► Biliary tract cancers: new data on immunotherapy
This study is led by Dr. Cindy Neuzillet, gastroenterologist at Institut Curie.
"Durvalumab (D) plus tremelimumab (T) immunotherapy in patients (Pts) with advanced biliary tract carcinoma (BTC) after failure of platinum-based chemotherapy (CTx): Interim results of the IMMUNOBIL GERCOR D18-1 PRODIGE-57 study. Session « Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary ».
Poster available on June 4 at 2:00pm (French time).
HEMATOLOGY
► Mantle cell lymphoma: what are the results of a new combination of a targeted therapy and immunotherapy?
With approximately 600 patients diagnosed each year in France, mantle cell lymphoma represents 2 to 10% of lymphomas. These are non-Hodgkin's lymphomas (NHL) that affect the B lymphocytes of the immune system in a region of the lymph node, called the "mantle zone". These tumors are aggressive and relapse is common. In recent years, new treatments and clinical trials have emerged that may change the landscape for patients. This is the case of the SHINE study, which evaluated the efficacy of a targeted therapy (a Bruton tyrosine kinase inhibitor) combined with immuno-chemotherapy in first-line treatment.
Professor Steven Le Gouill, hematologist and director of Institut Curie's Hospital Complex, coordinated the study in France. The main results of the SHINE study will be presented in an oral presentation at ASCO and published in the New England Journal of Medicine.
| Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL). Session « Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia ». Oral presentation on June 3 at 8:24pm (French time). |
NANOPARTICULES
► ENT cancers: a phase-3 trial is underway
Prof. Christophe Le Tourneau, oncologist and head of the early trials department at Institut Curie, is leading ths international comparative phase-3 trial.
NANORAY-312: A phase III pivotal study of NBTXR3 activated by investigator’s choice of radiotherapy alone or radiotherapy in combination with cetuximab for platinum-based chemotherapy-ineligible elderly patients with locally advanced head and neck squamous cell carcinoma. Session “Head and Neck Cancer »
Poster available on June 6 at 2:00pm (French time).
SUPPORTIVE CARE
► « Early together », a brand-new trial in metastatic uveal melanoma
The multi-center phase-3 clinical trial “Early Together” is coordinated by Dr. Sophie Piperno-Neumann, oncologist at Institut Curie.
Early together: A randomized phase III study of early palliative care in metastatic uveal melanoma (MUM). Session « Melanoma/Skin Cancers”.
Poster available on June 6 at 2:00pm (French time)
THEME-BASED TALKS
► Lymphoma
Dr. Carole Soussain, hematologist at Institut Curie, is invited to ASCO to share her expertise during a lecture on the treatment of brain lymphomas.
”Contemporary Treatment of Patients with Primary Central Nervous System Lymphoma” Ticketed Session “Meet the Professors: Comprehensive Care of Patients With Primary Central Nervous System Lymphoma”
June 6 at 5:00pm.
► Pediatric cancers
Dr. Franck Bourdeaut, pediatric oncologist at Institut Curie, will lead a session devoted to immunotherapy in pediatric cancers. He will present his work on rhabdoid tumors and the discovery of an immune reaction that point to the possibility of conducting clinical trials in immunotherapy to treat children with these rare tumors.
"SMARCB1-Deficient Tumors: A Unique Opportunity for Checkpoint Inhibitor Therapy"
June 6 at 8:15pm.